|
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion.
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors. The therapy is designed to target PI3Ka gene mutations.
“We look forward to leveraging the great work of the Scorpion team to date, along with Lilly’s deep expertise in breast cancer, to further advance STX-478 with speed and focus,” Jacob Van Naarden, executive vice president and president of Lilly Oncology, said in written remarks.
The deal expands Lilly’s oncology pipeline. STX-478 potentially could address 30% to 40% of patients with hormone-positive breast cancer, according to Lilly. Read more.
IU School of Medicine lands $3.2M grant for stem cell research
Indiana University School of Medicine scientists have been awarded a $3.2 million federal grant for research that could expand stem cell therapies and lead to new treatments for leukemia and other blood disorders. The scientists will explore how to boost hematopoietic stem cells, whose ability to self-renew and regenerate damaged cells makes them invaluable for treating blood diseases through transplantation. Read more.
Q&A with Kristin Sherman: Life sciences veteran is fighting for women’s health
Kristin Sherman has worked in nearly every part of Indiana’s health care and life sciences world, from drugmaker Eli Lilly and Co. to a huge medical device company to numerous biotech startups to the top of Community Health Network as board chair. Her 37-year career has given her a wide perspective on Indiana’s competitiveness in this critical sector of the economy, which employs tens of thousands of people and provides services to millions across the Hoosier state.
She is now trying to lead startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human papillomavirus infections before cancer develops and to treat HPV cancers after detection. Read more.
Novilytic Enters Exclusive Distribution Partnership With Avantor
WEST LAFAYETTE, Ind. (Jan. 22, 2024) – Novilytic, an innovator in molecular recognition technology, is proud to announce an exclusive distribution partnership with Avantor, a global supplier of discovery-to-delivery solutions and the parent company of VWR. Read more.
Notre Dame researchers partner with Mexico hospital to develop childhood cancer care monitoring tool
For a child battling cancer, an unexpectedly high temperature can initiate a race against time to reach providers who can treat and monitor symptoms. And for families in low- and middle-income communities in Mexico, pediatric cancer care is even more of a challenge. Fragmented healthcare systems, the absence of trackable health data, and a lack of access to healthcare facilities with readily available resources are fueling a race not easily won.
Now, a study to evaluate the preliminary design and usability of a cooperative cancer monitoring tool has published successful findings that may address this gap in care. Read more.
INSIDE INDIANA BUSINESS on Sanondaf establishing Indiana Headquarters - Watch the interview below!
| 
